Drug
Vorbipiprant clinical trials
Also written CR6086.
- studies test it
- 3
- open now
- 1
- in phase 3
- 0
- first study started
- 2017
Keep track of what changes. Save the vorbipiprant studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
3 studies that test it; most in 2017 (1)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2021 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 2 · Other 1
Rottapharm Biotech (2) · Gruppo Oncologico del Nord-Ovest (1)
Often tested with
Tested in the same studies.
Balstilimab (2) · Trastuzumab deruxtecan (1) · Durvalumab (1) · Panitumumab (1) · Botensilimab (1) · Sotorasib (1) · Nivolumab (1) · Amivantamab (1)
Studies
Open first, then newest update. How each study uses vorbipiprant is read from its arms, and is right about nine times in ten.
Testing it · 3
- Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)RecruitingPhase 2Gruppo Oncologico del Nord-OvestNCT05845450Written as Vorbipiprant
- Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI CancersActive, not recruitingPhase 1/2Rottapharm BiotechNCT05205330Written as CR6086
- A Study of the EP4 Antagonist CR6086 in Combination With Methotrexate, in DMARD-naïve Patients With Early Rheumatoid ArthritisCompletedPhase 2Rottapharm BiotechNCT03163966Written as CR6086
Codes
What other systems call vorbipiprant · ClinicalTrials.gg INT017933
- UNII (FDA) SS2LQQ8094VORBIPIPRANTOne source FDA
- NCI Thesaurus C186659VorbipiprantOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | SS2LQQ8094 | VORBIPIPRANT | One source FDA |
| NCI Thesaurus | C186659 | Vorbipiprant | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.